Inactive Instrument

Eurofarma Laboratórios S.A.

Equities

EUFA3

BREUFAACNOR4

Abcuro, Inc. announced that it has received $155 million in funding from a group of investors

August 16, 2023

On August 17, 2023, Abcuro, Inc. closed the transaction. The company has received $155,000,000 in the transaction. The oversubscribed round of funding co-led by new investors, Bain Capital Life Sciences Investors, LLC, and Redmile Group, LLC.

The transaction included participation from returning investors, Sanofi Ventures, Samsara BioCapital LLC, Mass General Brigham Ventures, LLC, RA Capital Management, L.P., Pontifax Venture Capital, and new investors, Soleus Capital Management, L.P., New Leaf Venture Partners, LLC, Eurofarma Laboratórios S.A., Tekla Capital Management LLC, and BlackRock, Inc. The company has received $120,141,750 from 21 investors pursuant to exemption provided under Regulation D. The round is raised at a post-money valuation of $271,448,274.

Latest news about Eurofarma Laboratórios S.A.

Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Eurofarma Laboratórios S.A. acquired Genfar S.A. from Sanofi.	28/09/23	CI
Abcuro, Inc. announced that it has received $155 million in funding from a group of investors	16/08/23	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Abcuro, Inc. announced that it expects to receive $199.522752 million in funding from Redmile Group, LLC, and other investors	10/08/23	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	26/03/23	CI
Eurofarma Laboratórios S.A. agreed to acquire Genfar S.A. from Sanofi for approximately ?300 million.	07/03/23	CI
Eurofarma Laboratórios S.A. acquired Laboratório Canonne for BRL 725 million.	14/12/22	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	14/08/22	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
Pfizer Inc. and BioNTech SE Announce Collaboration with Eurofarma Laboratórios SA to Manufacture COVID-19 Vaccine Doses for Latin America	26/08/21	CI
Eurofarma Laboratórios S.A. cancelled the acquisition of a portfolio of 12 products in Latin America from Hypera S.A..	16/03/21	CI
Eurofarma Laboratórios S.A. entered into agreement to acquire A portfolio of 12 products in Latin America from Hypera S.A. for approximately $160 million.	16/03/20	CI
Biotoscana Confirms Divestiture Negotiations	09/10/19	CI
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries Through Extended Agreement with Eurofarma Laboratórios	26/09/17	CI
Eurofarma Laboratórios S.A. acquired factory in Argentina of Sanofi.	17/09/15	CI
Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A	11/01/15	CI
Melinta Therapeutics, Inc. announced that it has received $15 million in funding from Eurofarma Laboratórios S.A.	07/01/15	CI
Eurofarma Laboratorios Ltda. acquired Laboratorios Laprin, S.A.	04/07/13	CI

Chart Eurofarma Laboratórios S.A.

Duration

Period

More charts

Company Profile

Sector

More about the company